The Center for Public Integrity, February 11, 2016. Across America, lobbyists for drugmakers — including Enbrel’s maker Amgen — have worked at a feverish pace to push state laws that make it harder for pharmacists to substitute cheaper biosimilars for brand-name biologic drugs, as is commonly done with regular generic drugs.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
FDA Approval Pending for Implant to Treat Opioid Addiction
Maine Public Broadcasting News, March 22, 2016. Dr. Tracy Rupp shares the concern that patients with the opioid addiction treatment implant needed to take additional doses of buprenorphine. From a patient safety standpoint, she expresses her concern and hopes for further studies about the risks and benefits for patients who get the implant.
Read More »FDA to Shift Clinical Evidence for Medical Devices Toward Postmarket
Medical Design Technology, April 4, 2016. The National Center for Health Research expresses that Advancing Breakthrough Devices for Patients Act of 2015 encourages companies to get medical products on the market quickly as opposed to focusing on patient safety and product efficiency.
Read More »Possible Drug Risks Buried in Delayed FDA ‘Watch Lists’
Medscape Medical News, March 29, 2016. Dr Diana Zuckerman explains that publication delays of drug watch lists illustrate how the FDA caters more to drug manufacturers than patients.
Read More »Can an Implant Stop Heroin Addiction?
The Daily Beast, March 27, 2016. Tracy Rupp told the advisory committee at the FDA that she was “disappointed to conclude” that the evidence wasn’t enough for her to endorse the opioid addition treatment. “While we all desperately want new treatments for opioid abuse, we have to be sure they are safe and effective,” she said.
Read More »